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Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been
associated with an aggressive tumour phenotype and adverse outcome in several cancer types. We recently
demonstrated that overexpression of PODXL is an independent factor of poor prognosis in colorectal cancer (CRC).
The aim of this study was to validate these results in two additional independent patient cohorts and to examine
the correlation between PODXL mRNA and protein levels in a subset of tumours.
Method: PODXL protein expression was analyzed by immunohistochemistry in tissue microarrays with tumour
samples from a consecutive, retrospective cohort of 270 CRC patients (cohort 1) and a prospective cohort of 337
CRC patients (cohort 2). The expression of PODXL mRNA was measured by real-time quantitative PCR in a subgroup
of 62 patients from cohort 2. Spearman´s Rho and Chi-Square tests were used for analysis of correlations between
PODXL expression and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards
modelling were applied to assess the relationship between PODXL expression and time to recurrence (TTR), disease
free survival (DFS) and overall survival (OS).
Results: High PODXL protein expression was significantly associated with unfavourable clinicopathological
characteristics in both cohorts. In cohort 1, high PODXL expression was associated with a significantly shorter 5-year
OS in both univariable (HR = 2.28; 95% CI 1.43-3.63, p = 0.001) and multivariable analysis (HR = 2.07; 95% CI 1.25-3.43,
p = 0.005). In cohort 2, high PODXL expression was associated with a shorter TTR (HR = 2.93; 95% CI 1.26-6.82,
p = 0.013) and DFS (HR = 2.44; 95% CI 1.32-4.54, p = 0.005), remaining significant in multivariable analysis, HR = 2.50;
95% CI 1.05-5.96, p = 0.038 for TTR and HR= 2.11; 95% CI 1.13-3.94, p = 0.019 for DFS.
No significant correlation could be found between mRNA levels and protein expression of PODXL and there was
no association between mRNA levels and clinicopathological parameters or survival.
Conclusions: Here, we have validated the previously demonstrated association between immunohistochemical
expression of PODXL and poor prognosis in CRC in two additional independent patient cohorts. The results further
underline the potential utility of PODXL as a biomarker for more precise prognostication and treatment stratification
of CRC patients.Background
CRC is the third most common type of cancer in the
world with an annual worldwide incidence of more than
one million cases [1]. Early detection, adequate surgical
excision and optimal use of adjuvant treatment are of
critical importance for the clinical outcome. Currently,
tumour stage at diagnosis is the most important* Correspondence: anna_h.larsson@med.lu.se
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reproduction in any medium, provided the orprognostic factor and adjuvant chemotherapy is recom-
mended for all patients with stage III disease to reduce
the relative risk of recurrence with approximately 30%.
The role of adjuvant chemotherapy in stage II disease is
more unclear, and there is an ongoing debate on how to
identify patients with high-risk disease who have a greater
risk of recurrence and might benefit from adjuvant ther-
apy. According to ASCO guidelines, adjuvant treatment
should be considered for patients with stage II disease pre-
senting with one or more risk factors (including large
tumour, tumour perforation, vascular or neural invasionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a great need for new prognostic and treatment predictive
biomarkers to select patients with high-risk disease, but
despite many efforts no well-validated molecular markers
have yet been incorporated into clinical pratice.
Podocalyxin-like 1 (PODXL) is an anti-adhesive trans-
membrane protein belonging to the CD34 family. PODXL
inhibits cell-cell interaction through charge-repulsive
effects and in normal tissues, its presence has classically
been ascribed to hematopoetic progenitor cells [4], vascular
endothelial cells [5] and renal glomerular podocytes where
it plays a vital part in maintaining filtration pathways [6].
Loss of PODXL expression has been observed in glomeru-
lopathies primarily associated with the nephrotic syndrome
[7]. PODXL has been associated with an aggressive tumour
phenotype and adverse outcome in several cancer types [8]
[9,10]. The mechanisms behind these observations are not
fully known, but PODXL has been shown to interact with
mediators of metastasis [9,11] and to play an important
role in epithelial-mesenchymal transition (EMT) [12]. A
recent study demonstrated that forced PODXL expression
in ovarian cancer cells decreased their adhesivity by alter-
ing β1-integrin levels, and that PODXL expression on the
cell surface was associated with poor prognosis in high
grade serous carcinomas [13]. PODXL has also been
demonstrated as being a target of tumour suppressive
miRNA-199 in testicular cancer [14].
In a previous study, we have demonstrated that mem-
branous expression of PODXL is associated with unfavour-
able clinicopathological characteristics and independently
predicts a poor prognosis in CRC [15]. The aim of this
study was to validate these results in two additional inde-
pendent patient cohorts with a total number of 590 CRC
cases. A secondary aim was to examine the correlation be-
tween PODXL mRNA and protein levels and its clinical
significance in a subset of the tumours.
Methods
Patients
Cohort 1 is a consecutive, retrospective cohort compris-
ing all patients who underwent surgery for CRC at
Skåne University Hospital in Malmö, Sweden between 1
January 1990 and 31 December 1991, for whom archival
tumour tissue was available (n = 270). The cohort has
been described in detail previously [16].
Cohort 2 consisted of 337 patients undergoing surgery
for CRC at the Central District Hospital in Västerås, Swe-
den between June 2000 and December 2003. Tumour tis-
sue for tissue microarray (TMA) construction was
available from 320 (95%) patients. Follow-up started at
date of diagnosis and ended at death or 15 April 2010 [16]
[17]. Endpoints were defined according to Punt et al [18].
All observations were censored at loss to follow-up and at
the end of the study period.Information on vital status and cause of death was
obtained from the Regional Oncology Registry and hos-
pital records. Histopathological, clinical and treatment
data were obtained from pathology and hospital records.
Information on recurrence, cause-specific survival and
adjuvant therapy was not available for cohort 1.
Patient and tumour characteristics are summarized in
Table 1.
Approvals for the present study was obtained from the
Ethics Committees at Lund University (ref. 447/2007)
and Uppsala University (00/001).
Tissue microarray construction
Areas representative of cancer were marked on haema-
toxylin and eosin stained slides and TMAs were con-
structed as previously described [19]. In brief, two 1.0 mm
cores were taken from each tumour and mounted in a
new recipient block using a semi-automated arraying de-
vice (TMArrayer, Pathology Devices, Westminster, MD,
USA). Non-necrotic tumour areas were avoided and, when
possible, one core was taken from the centre and periph-
ery of the tumour, respectively.
Immunohistochemistry and antibody validation
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an
Autostainer Plus (DAKO, Glostrup, Denmark) with the
affinity-purified polyclonal anti-PODXL antibody HPA
2110 (Atlas Antibodies, Stockholm, Sweden, diluted
1:250). The specificity of this antibody, originally gener-
ated within the Human Protein Atlas (HPA) project, has
been validated using Western blotting and protein arrays
and PODXL protein expression has been mapped by
IHC in 48 types of normal tissues and 20 common can-
cers [20,21] (www.proteinatlas.org). The same antibody
was used to detect PODXL expression in CRC in our
previous study [15] and in the study on testicular cancer
by Cheung et al. [14].
Evaluation of PODXL staining
PODXL expression was recorded as negative (0), weak
cytoplasmic positivity in any proportion of cells (1),
moderate cytoplasmic positivity in any proportion (2),
distinct membranous positivity in ≤50% of cells (3) and
distinct membranous positivity in >50% of cells (4) as
previously described [15]. The staining was evaluated by
two independent observers (AL and KJ) who were
blinded to clinical and outcome data. Scoring differences
were discussed in order to reach consensus.
Real-time quantitative PCR
PODXL mRNA expression was analyzed in 62 fresh fro-
zen tumours from patients in cohort 2. Total RNA
Table 1 Association between PODXL protein expression and clinicopathological parameters
Protein expression cohort 1 Protein expression cohort 2
n (%) low 235(90.4) high 25(9.6) p-value low 291(92.1) high 25(7.9) p-value
Age
<=75 130(55.3) 16(64.0) 0.406 166(57.0) 137(69.9) 0.625
>75 105(44.7) 9(36.0) 125(43.0) 59(30.1)
Gender
Female 116(52.2) 14(65.2) 0.528 143(49.1) 13(52.0) 0.784
Male 119(47.8) 11(34.8) 148(50.9) 12(48.0)
T stage
1, 2 78(33.2) 8(32.0) 0.979 52(17.9) 1(4.0) 0.017
3 124(52.8) 14(56.0) 193(66.3) 15(60.0)
4 28(11.9) 3(12.0) 46(15.8) 9(36.0)
Missing 5(2.1)
N stage
0 154(65.5) 9(36.0) 0.005 179(61.7) 5(20.0) <0.001
1 53(22.6) 8(32.0) 57(19.7) 8(32.0)
2 23(9.8) 7(28.0) 54(18.6) 12(48.0)
Missing 5 (2.1) 1 (4.00)
M stage
0 201(85.5) 19(87.0) 0.150 262(90.0) 14(56.0) <0.001
1 31(13.2) 6(13.0) 29(10.0) 11(44.0)
Missing 3(1.3)
Location
Colon 189(78.3) 22(78.3) 0.376 194(66.7) 16(64.0) 0.057
Rectum 45(21.7) 3(21.7) 97 (33.3) 9(36.0)
Missing 1
Differentiation grade
High-intermediate 181(80.4) 13(78.3) 0.006 233(80.1) 15(60.0) 0.019
Low 54(19.6) 12(21.7) 58(19.9) 10(40.0)
Vascular invasion
Absent 126(53.6) 6(95.7) 0.003 258(88.7) 18(72.0) 0.016
Present 101(43.0) 19(4.3) 33(11.3) 7(28.0)
Missing 8(3.4)
Neural invasion
Absent N/A N/A 286(98.3) 22(88) 0.002
Present 5(1.7) 3(12)
N/A – not analyzed
χ2-test of association was used for 2x2 tables and χ2-test for linear trend for tables with more than two rows and/or columns. The number of cases with missing
data is given for some variables, but these are not included in the analyses.
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synthesis (Reverse Transcriptase kit, Applied Biosystems,
Warrington, UK) and real-time quantitative PCR (qRT-
PCR) analysis with SYBR Green PCR master mix (Ap-
plied Biosystems) were performed. Quantification of ex-
pression levels was calculated by using the comparative
Ct method, normalization according to housekeepinggene PMM1 (forward primer: 5’-GCAAAGGGCTGA
GGTTCTC-3’, reverse primer: 5’-TCCCACCAGGGC
TAGTCTC-3’) [22]. For PODXL amplification, forward
primer with sequence 5’-GTAACTGGGCAAAGTGTG-
3’ and reverse primer with sequense 5’-CCTGCAC
AGAGGGTGTTT-3’ were used. All primers were
designed using OligoPerfect Designer (Invitrogen).
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For statistical purposes, categories of PODXL protein
expression were dichotomized into low (0–2) and high
(3–4) based on PODXL staining as previously described
[15], and mRNA levels into low and high according to
the mean value. Spearman´s Rho and Chi-square tests
were used for comparison of PODXL expression and
relevant clinicopathological characteristics. Kaplan-
Meier analysis and log rank test were used to illustrate
differences in TTR, DFS and 5-year OS according to
PODXL mRNA and protein expression. Cox regression
proportional hazards models were used for estimation of
hazard ratios (HR) for DFS and TTR according to
PODXL expression in both uni- and multivariable analysis
adjusted for age, gender, TNM status, differentiation
grade, neural and vascular invasion. A backward condi-
tional selection method was used for variable selection by
the model. All tests were two-sided. A p-value of 0.05 was
considered significant. All statistical analyses were per-
formed using SPSS version 19 (SPSS Inc, Chicago, IL).
Results
PODXL protein expression
Following antibody optimization and staining, PODXL
expression could be evaluated in 260/270 (96.3%)
tumours in cohort 1 and 316/320 (98.8%) tumours in co-
hort 2. In cohort 1, 137 (52.7%) tumours were negative
for PODXL (score 0), 98 (37.7%) tumours displayed
weak-moderate staining (score 1–2) and 25 (9.6%)
tumours displayed high PODXL expression (score 3–4).
In cohort 2, PODXL expression was denoted as negativeFigure 1 Immunohistochemical images representing various PODXL s
representing colorectal tumours with (A) negative tumour cells and positiv
membranous staining and (C,D) strong, membranous staining in a varying(score 0) in 198 (62.7%) tumours, weak-moderate (score
1–2) in 93 (29.5%) tumours and strong (score 3–4) in 25
(7.9%) tumours. Representative IHC images visualizing
different staining categories are shown in Figure 1.
Association between PODXL protein expression and
clinicopathological parameters
As shown in Table 1, high PODXL protein expression was
associated with more advanced N-stage (p= 0.005), low
differentiation grade (p= 0.006) and vascular invasion
(p= 0.003) in cohort 1 and with a more advanced T-stage
(p= 0.017), N-stage (p< 0.001), M-stage (p< 0.001), low
differentiation grade (p= 0.019) and presence of vascular
(p= 0.016) and neural invasion (p= 0.002) in cohort 2.
There was no significant correlation between PODXL ex-
pression and age at diagnosis, gender or tumour location
in either of the cohorts.
Overexpression of PODXL protein is associated with
shorter survival and time to recurrence
Kaplan Meier analysis demonstrated that high PODXL
protein expression correlated with a significantly worse
5-year OS in cohort 1 (p< 0.001) (Figure 2). These asso-
ciations were confirmed in Cox univariable analysis
(HR= 2.28; 95% CI 1.43-3.63, p = 0.001) and remained
significant in multivariable analysis adjusted for age, gen-
der, TNM status, differentiation grade and vascular inva-
sion (HR= 2.07; 95% CI 1.25-3.43, p = 0.005). In cohort
2, high PODXL expression was significantly associated
with a shorter TTR and DFS in curatively treated
patients (Figure 2). Cox univariable analysis confirmedtaining patterns. Immunohistochemical images of PODXL staining
e stromal vessels, (B) moderate cytoplasmic staining without
proportion of tumour cells.
Figure 2 High expression of PODXL protein is associated with a poor outcome in colorectal cancer patients. Kaplan-Meier analyses of (A)
5-year OS in cohort 1, (B) TTR and (C) DFS in cohort 2 according to PODXL expression.
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1.26-6.82, p = 0.013) and DFS (HR= 2.44; 95% CI 1.32-
4.54, p = 0.005) (Table 2), remaining significant in multi-
variable analysis adjusted for age, gender, T- and N- sta-
tus, differentiation grade, vascular and neural invasion,
HR= 2.50; 95% CI 1.05-5.96, p = 0.038 for TTR and HR=
2.11; 95% CI 1.13-3.94, p = 0.019 for DFS (Table 2).
There was no significant difference in outcome, neither
for TTR, DFS or OS, between patients with tumours
denoted as having negative, weak or moderate staining; i.
e. all categories lacking membranous staining had a simi-
lar prognosis (data not shown).Correlation beween PODXL mRNA levels and protein
expression, clinicopathological characteristics and outcome
PODXL mRNA levels were assessed in 62 fresh frozen
tumour specimens from cohort 2, comprising 21 tumours
with high protein expression and 41 tumours with low
protein expression. As visualized in Figure 3, there was no
significant correlation between PODXL mRNA levels and
protein expression (p= 0.656). Moreover, there was no sig-
nificant association between PODXL mRNA levels and
clinicopathological parameters (Additional file 1) or TTR,
DFS and 5-year OS (data not shown). mRNA levels did
not differ significantly between tumours lacking PODXL
expression compared with categories of any degree of ex-
pression (data not shown).Correlation between PODXL expression and response to
adjuvant chemotherapy
As it has been previously demonstrated that patients with
PODXL high tumours might benefit from adjuvant
chemotherapy [15] we also investigated the prognostic
value of PODXL in combined strata according to chemo-
therapy. The results revealed similar, however non-
significant, trends to the previous study, indicating that
patients with PODXL high tumours who were treated with
adjuvant chemotherapy had a similar DFS as patients with
low PODXL expressing tumours (Additional File 2).Table 2 Cox uni- and multivariable analysis of relative risks o




PODXL low 1,00 259(5
PODXL high 2.93(1.26-6.82) 0.013 14(6)
Multivariable
PODXL low 1,00 259(5
PODXL high 2.50(1,05-5.96) 0.038 14(6)
Multivariable analysis adjusted for age (>/<=75 years), gender, T-stage (I, II, III, IV), N
vascular invasion (absent, present).Discussion
The results from this validation study provide further evi-
dence that overexpression of PODXL protein is a pre-
dictor of poor prognosis in CRC, independent of tumour
stage or other clinicopathological characteristics. Together
with the results from our previous study [15], this correl-
ation has now been confirmed in three independent
cohorts representing more than 1000 patients in total.
Moreover, while the results from this study further con-
firm the association of high PODXL expression with a
reduced overall survival, its impact as a biomarker of
reduced time to recurrence and disease free survival in
curatively treated patients is also demonstrated.
While PODXL is expressed in the cytoplasm in a con-
siderable proportion of CRC tumours, it is mainly the
presence of distinct membranous staining, here denoted
as high expression, that seems to confer a poor progno-
sis [15]. The most aggressive tumours show a strong,
membranous staining in a subset of tumour cells at the
invasive tumour front, corresponding well to the mor-
phological term “tumour budding”, which has been
demonstrated to be of prognostic importance in CRC
[23,24], and biologically closely related to EMT [23]
[12]. These observations are also well in line with the
study by Cipollone et al, where PODXL expression on
the cell surface but not in the cytoplasm was signifi-
cantly associated with a shorter disease-free survival in
patients with high grade serous ovarian carcinoma [13].
In that study, it was also demonstrated that forced ex-
pression of PODXL in serous ovarian carcinoma-derived
OVCAR-3 cells resulted in localization of PODXL to the
cell surface, decreased cell adhesion to mesothelial
monolayers and diminished levels of β1-integrin, leading
the authors to conclude that PODXL may facilitate
transperitoneal metastasis of high grade serous carcin-
oma [13]. In light of the significant association of high
PODXL expression and increased T-stage, in particular
stage T4 tumours, observed in our previous study [15],
and in Cohort II in this study, it would be of interest to
perform further studies to investigate whether PODXLf time to recurrence and disease free survival in
protein expression
Disease free survival







stage (0,1,2), differentiation grade (high-intermediate, low), neural and
Figure 3 Association between PODXL gene and protein
expression in a subgroup of colorectal patients from cohort 2.
Boxplots of PODXL mRNA levels according to protein expression
(low-high). Horizontal lines indicate median.
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in CRC.
Since membranous staining of PODXL in most cases is
seen in only a fraction of tumour cells, these tumours do
not necessarily have the highest level of protein in total
and overexpression of protein will not be reflected in high
mRNA levels. Hence, evaluation of PODXL expression
should be based on a qualitative rather than quantitative
assessment and IHC has several advantages over other
types of assays in terms of clinical applicability as it is a
comparatively simple, fast and inexpensive method.
Considering the prognostic importance of protein
localization, the lack of a significant correlation between
PODXL mRNA and protein expression levels, clinico-
pathological characteristics and survival is not surpris-
ing. Moreover, being a CD34-related protein, PODXL is
expressed on vascular surfaces [25], and thus, present in
various amounts in the tumour-associated stroma.
It should also be pointed out that previous studies
attempting to determine a direct correlation between
mRNA levels and protein expression in tumours have
shown divergent results, and analyses indicate that protein
concentrations correlate with the corresponding mRNA
levels by only 20-40 % [26,27]. In some cases, such as
HER2/neu, expression levels show highly significant correl-
ation [28], but in other studies regarding molecular markers
in adenocarcinoma of the lung [29] and in prostate cancer
[30], a relationship between mRNA and protein was not
observed. There are several possible explanations for these
discrepancies, e.g. post-translational modifications, varia-
tions in protein half-life and actual biological differences be-
tween mRNA and protein abundance. In addition, there are
potential experimental errors to be considered, includinganatomical origin and quality of tissue. A more comprehen-
sive analysis of the correlation between PODXL mRNA
and protein expression might be provided by performing
microdissection of strongly staining areas from frozen
tumour sections. In the clinical setting, however, it is evi-
dent that immunohistochemical assessment of PODXL is
the method of choice, whereby recognition of its location
on the cellular surface should be quite straightforward.
Some limitations related to the TMA-technique must be
considered, not least its ability to accurately reflect the ex-
pression of heterogenously expressed markers. One way to
compensate for this is to, whenever possible, ensure that
tumour cores are sampled from different tumour areas, i.e.
the invasive front and centre, respectively. While this had
been done for the majority of the here analyzed tumours, it
should be pointed out that tumour areas denoted as having
distinct membranous PODXL expression could not only
be found at the invasive front, but also in scattered areas
within the tumour. However, we have previously compared
results from paired TMA-cores with full-face sections with
excellent concordance [15]. Moreover, assessment of full-
face sections from prospectively collected clinical samples
have reveled a similar proportion of CRC cases with high
PODXL expression as reported here and in our previous
study (unpublished observations).
In both cohorts in this study, the proportion of
tumours denoted as having high PODXL expression was
lower compared to our previous study, where 13.4% of
the tumours displayed high PODXL expression [15].
Given the observed association between PODXL expres-
sion and a more advanced disease stage, this can be
explained by the fact that the two cohorts examined here
had a lower percentage of patients with stage IV disease
(9.6 vs 7.9%) compared to the population-based pro-
spective cohort used in the previous study (18.3%).
Furthermore, in patients with stage III disease in cohort
2, a trend towards the previously demonstrated benefit
from adjuvant chemotherapy could be observed for
patients with high tumour-specific PODXL expression,
who had a similar DFS and OS as patients with PODXL-
low tumours [15]. Although this did not reach statistical
significance, most likely due to the smaller subgroup avail-
able for analysis, these findings further indicate that
patients with high PODXL-expressing tumours might
benefit from adjuvant treatment. As adjuvant chemother-
apy is given to the majority of patients with stage III disease
according to current treatment protocols, assessment of
PODXL expression might be particularly relevant in order
to identify high-risk patients with stage II disease. Similar
to our previous study [15] the number of patients with
stage II disease in this study who received adjuvant treat-
ment were too few for a meaningful statistical analysis.
Hence, these associations should be confirmed in larger
retrospective studies or within randomized treatment trials.
Larsson et al. BMC Cancer 2012, 12:282 Page 8 of 9
http://www.biomedcentral.com/1471-2407/12/282Conclusions
In conclusion, we have validated the previously demon-
strated association between immunohistochemical expres-
sion of PODXL, defined as distinct membranous staining,
and poor prognosis in CRC. The results further underline
the potential utility of PODXL as a biomarker for more
precise prognostication and treatment stratification of
CRC patients. In light of the prognostic relevance of the
subcellular localization of PODXL and the observed lack
of a significant correlation between PODXL mRNA levels
and protein expression, it is evident that IHC remains the
most suitable method for assessment of PODXL protein
expression in the clinical setting.
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